Discontibuation of oral ULT

Phase 2Small molecule

AAssistance Publique - Hôpitaux de Paris

Discontibuation of oral ULT is one of 7 small molecule programs targeting Randomised Controlled Trial. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Randomised Controlled TrialNot yet recruiting

Randomised Controlled TrialPhase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Randomised Controlled Trial

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 2

1 2

Zytiga

Johnson & Johnson

Phase 2

1 3

N-Acetyl Cyteien

SStanford University

Phase 3

1 4

Platelet Rich Fibrin

GGovernment Dental College and Research Institute, Bangalore

Phase 2

1 5

Olinvyk

TTrevena Inc.

Preclinical

1 6

Discontibuation of oral ULT

AAssistance Publique - Hôpitaux de Paris

Phase 2

1 7

Botulinum Toxins

YYale University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Not yet recruiting

Randomised Controlled Trial

NCT06956885

Clinical

Trials by Indication[1]

Randomised Controlled Trial1 trial

Maintenance or Withdrawal of Urate Lowering Therapy According to Ultrasound Features in Gout Patients: a Randomised Controlled Trial Stop Treatment In Gout

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06956885·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Discontibuation of oral ULT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Discontibuation of oral ULT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Discontibuation of oral ULT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAssistance Publique - Hôpitaux de Paris

Discontibuation of oral ULT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Randomised Controlled Trial1 trial

References

Drug Info

Quick Facts

Related News